From wiki-pain
Revision as of 07:23, 24 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1996
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 5
Total Number 5
Disease Relevance 1.92
Pain Relevance 3.11

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (BDKRB2) plasma membrane (BDKRB2) signal transducer activity (BDKRB2)
Anatomy Link Frequency
IMR-90 1
Hyp3 1
BDKRB2 (Homo sapiens)
Pain Link Frequency Relevance Heat
bradykinin 64 100.00 Very High Very High Very High
b2 receptor 20 100.00 Very High Very High Very High
antagonist 19 100.00 Very High Very High Very High
B1 receptor 3 100.00 Very High Very High Very High
aspirin 9 99.64 Very High Very High Very High
Pain 10 89.96 High High
Inflammation 10 89.60 High High
agonist 3 75.00 Quite High
dorsal root ganglion 2 75.00 Quite High
cva 1 73.44 Quite High
Disease Link Frequency Relevance Heat
Brain Injury 25 99.84 Very High Very High Very High
Hereditary Angioedema 35 96.00 Very High Very High Very High
Pain 9 89.96 High High
INFLAMMATION 10 89.60 High High
Critical Illness 2 85.08 High High
Death 2 84.24 Quite High
Ganglion Cysts 2 75.00 Quite High
Cv General 3 Under Development 1 73.44 Quite High
Adenoma 1 64.00 Quite High
Hepatitis 1 62.76 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These results suggest that aspirin is an allosteric inhibitor of the B2 receptor, a property that may be involved in its therapeutic actions.
Negative_regulation (inhibitor) of B2 receptor associated with aspirin and b2 receptor
1) Confidence 0.57 Published 2008 Journal Biochem. Pharmacol. Section Abstract Doc Link 18355801 Disease Relevance 0.17 Pain Relevance 1.02
Incubation of IMR-90 cells with BK (100 nM) led to a loss (89%) of B2R with a half-life (T(1/2)) of 7.0 min.
Negative_regulation (loss) of B2R in IMR-90 associated with bradykinin
2) Confidence 0.56 Published 1999 Journal Mol. Pharmacol. Section Abstract Doc Link 10419551 Disease Relevance 0.26 Pain Relevance 0.78
Although this is the largest trial of a Bradykinin B2 receptor antagonist in TBI conducted so far, it was small, and even in aggregate the total number of participants in clinical trials of B2 Receptor antagonists is less than 400 patients.
Negative_regulation (antagonist) of B2 receptor associated with antagonist, b2 receptor and brain injury
3) Confidence 0.32 Published 2009 Journal Trials Section Body Doc Link PMC2794266 Disease Relevance 0.62 Pain Relevance 0.26
Icatibant (Firazyr®; Shire), a bradykinin B2 receptor inhibitor, was licensed in the EU, Switzerland, Lichtenstein and Iceland in July 2008 for treatment of acute HAE-related swellings.
Negative_regulation (inhibitor) of B2 receptor associated with hereditary angioedema and b2 receptor
4) Confidence 0.12 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941790 Disease Relevance 0.65 Pain Relevance 0.08
Blocking the bradykinin binding at the B1 receptor with (Des-Arg10)-Lys-bradykinin and at the B2 receptor with D-Arg(Hyp3-Thi5.8-D-Phe7)-bradykinin, respectively, revealed that in 0.75-day-old cultures no or only a very small amount of B1 receptors are present.
Negative_regulation (Blocking) of B2 receptor in Hyp3 associated with b1 receptor, b2 receptor and bradykinin
5) Confidence 0.12 Published 1996 Journal Neuroscience Section Abstract Doc Link 8938754 Disease Relevance 0.22 Pain Relevance 0.97

General Comments

This test has worked.

Personal tools